TVD 2017

PET: Weaknesses

• Needs matching with morphological techniques • PET/CT or PET/MRI hybrid scanners • Possible matching errors in moving structures • Size of hot areas dependent on windowing • Does not show real tumour extension • FDG-PET not necessarily tumour-specific • Uptake in inflammatory conditions • Some tumours need specific tracers • 68 Ga-DOTATOC for neuroendocrine tumours • PSMA ligand for prostate cancer